期刊文献+

胺碘酮联合尤尼清对快速心房颤动转复的疗效观察

Effect of Youniqing combined with Amiodarone on cardioversion of atrial fibrillation
下载PDF
导出
摘要 目的观察尤尼清(环磷腺苷葡胺meglumine cyclic adenylate,MCA)加强胺碘酮对阵发性快速心房颤动的转复效果。方法将该院急诊科2006年1月~2009年1月198例阵发性心房颤动患者分为胺碘酮治疗组(A组)和尤尼清+胺碘酮治疗组(B组)。观察治疗12、24和72h转律成功率及有效控制心室率时间。结果尤尼清+胺碘酮组12、24和72h转律成功率分别为76.47%、88.24%和90.20%,胺碘酮组12、24和72h转律成功率分别为63.54%、76.04%和79.17%,差异有统计学意义(P<0.05)。尤尼清+胺碘酮组6h和12h心室率控制率分别为86.31%和99.02%,明显高于胺碘酮组69.79%和90.63%,两组相比差异有统计学意义(P<0.01)。结论对阵发性快速心房颤动患者进行胺碘酮转律治疗时,加用尤尼清可增加转律成功率,缩短转律所需时间,并有效降低心室率。 [Objective] To observe whether the Youniqing (meglumine cyclic adenylate, MCA) could enhance the recovery effect of Amiodarone on paroxysmal atrial fibrillation (AF). [Methods] From January 2006 to January 2009, a total of 198 patients with paroxysmal atrial fibrillation in emergency department of shengjing hospital were divided into two group: group A (Amiodarone) and group B (Youniqing and Amiodarone). The rate of cardioversion of AF and the effective control time of ventrieular rate in 12, 24 and 72 h after therapy was investigated. [Results] The rate of cardioversion of AF is 76.47%, 88.24% and 90.20%, respectively, at 12, 24 and 72 h in group B, and 63.54%, 76.04% and 79.17% in group A. There was statistical Significance difference (P 〈0.05). The ventricular rate in group B (86.31% and 99.02%) is significandy higher than group A (69.79% and 90.63%) at 6 h and 12 h. The difference is of statistical significance (P 〈0.05). [Conclusions] The results of this study suggest that in the therapy to AF patients, the combination of amiodarone with Youniqing can raise the achievement ratio of cardioversion, shorten the cardioversion time, and decrease the ventrieular rate.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2009年第10期1585-1587,共3页 China Journal of Modern Medicine
关键词 心房颤动 环磷腺苷葡胺 胺碘酮 尤尼清 atrial fibrillation meglumine cyclic adenylate Amiodarone youniqing
  • 相关文献

参考文献7

  • 1胡小菁,吕安林.房颤病因及发病机制研究进展[J].实用医院临床杂志,2007,4(2):79-81. 被引量:6
  • 2ARMON C. Amiodarone for atrial fibrillation[J]. N Engl J Med, 2007, 356(23): 2424-2426.
  • 3ZIMETBAUM P. Amiodarone for atrial fibrillation[J]. N Engl J Med, 2007, 356(9): 935-941.
  • 4LONDON B. Amiodarone and atrial fibrillation[J]. J Cardiovase Electrophysiol, 2007, 18(12): 1321-1322.
  • 5CHANDHOK S, SCHWARTZMAN D. Amiedarone therapy for atrial rhythm control: insights gained from a single center experience [J]. J Cardiovasc Electrophysial, 2007, 18(7): 714-718.
  • 6郭林妮,黄元铸,蒋文平,李庚山,陆再英,戚文航,任自文,吴宁,向晋涛,朱俊,方圻,高润霖.胺碘酮抗心律失常治疗应用指南[J].中国心脏起搏与心电生理杂志,2004,18(6):401-407. 被引量:392
  • 7郭林妮 黄元铸 蒋文平 等.胺碘酮抗心律失常治疗应用指南.实用医学杂志,2007,23(20):3266-3267.

二级参考文献26

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1398
  • 2[2]Stafford RS,Singer DE.National patterns of warfarin ues in atrial fibrillation[J].Arch Intern Med,1996,156 (22):2537-2541.
  • 3[3]Fuster V,Rydén LE,Asinger RW,et al.ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology[J].Circulation,2001,104 (17):2118-2150.
  • 4[4]Benjamin RJ,Levy D,Vaziri SM,et al.Independent risk factors for atrial fibrillation in a population-based cohort:the Framingham Heart Study[J].JAMA,1994,271 (11):840-844.
  • 5[5]Vaziri SM,Larson MG,Benjamin EJ,et al.Echocardiographic predictors of nonrheumatic atrial fibrillation:the Framingham Heart Study[J].Circulation,1994,89 (2):724-730.
  • 6[6]Verdecchia P,Reboldi G,Gattobigio R,et al.Atrial Fibrillation in hypertension:predictors and outcome[J].Hypertension,2003,41 (1):218-23.
  • 7[7]Tsang TS,Barnes ME,Bailey KR,et al.Left atrial volume:important risk marker of incident atrial fibillation in 1655 older men and women[J].Mayo Clin Proc,2001,76(5):467-475.
  • 8[8]Gerdts E,Oikarinen L,Palmieri V,et al.Correlates of left atrial size in hypertension patient with left ventricular hypertrophy:the Losartan Intervention For Endpoint Reduction in Hypertension (life) Investigators[J].AM Heart J,1999,3:494-499.
  • 9[9]Kowey PR,Taylor JE,Rials SJ,et al.Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting[J].Am J Cardiol,1992,69(9):963-965.
  • 10[10]Asher CR,Miller DP,Grimm RA,et al.Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery[J].Am J Cardiol,1998,82(7):892-895.

共引文献395

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部